Dr. Morgan on the Future of Myeloma Treatment

Gareth Morgan
Published: Friday, Jan 02, 2015



Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

 He advocates the investigation of unique treatment plans specifically targeted for each patient population. In the next one or two years, Morgan predicts that oncologists treating multiple myeloma will first do a sequence analysis to determine an individualized treatment based on the pattern of mutations seen in that patient. 

 His research has found that 50% of all the mutations within myeloma are actionable.

SELECTED
LANGUAGE


Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

 He advocates the investigation of unique treatment plans specifically targeted for each patient population. In the next one or two years, Morgan predicts that oncologists treating multiple myeloma will first do a sequence analysis to determine an individualized treatment based on the pattern of mutations seen in that patient. 

 His research has found that 50% of all the mutations within myeloma are actionable.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x